Equity

Genmab A/S (GMAB) Stock — Today's Move

▲ +2.04%

$44.69

+$0.89 today

GMAB is up 2.04% today. Volume is 7.44M vs a 30-day average of 4.14M (1.80x).

Day High

$45.45

Day Low

$44.08

Open

$44.79

Prev Close

$43.79

Volume

7.44M

Avg Vol (30d)

4.14M

52-Wk High

$45.45

52-Wk Low

$23.62

Sector

—

Today's Move

+2.04%

Next Earnings

Not in next 6 wks

52-wk low $23.6252-wk high $45.45

GMAB is 97% of the way from its 52-week low to its high.

Indicators:

Close price · volume bars (dashed line = average volume) · news that day (2M–1Y) — hover or tap the chart. Indicators are for education, not trading advice.

Why is GMAB moving today?

Yahoo· Oct 26, 3:08pm

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types a…

Yahoo· Oct 26, 2:25pm

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Yahoo· Oct 26, 11:00am

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

COPENHAGEN, Denmark, October 26, 2026--Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific a…

Yahoo· Oct 25, 11:00am

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

COPENHAGEN, Denmark, October 25, 2026--Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-b…

Yahoo· Oct 24, 11:01am

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtam…

Related Movers

▼ -48.36%

XP Inc.

Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session

$15.71 -$14.71

Vol: 132.61M (13.2x avg) Financial Services

INTR

▼ -34.91%

Inter & Co. Inc.

S&P Index Addition Could Change The Case For Inter (INTR) Stock

$4.68 -$2.51

Vol: 55.63M (7.3x avg) Banking

BBD

▼ -28.01%

Banco Bradesco Sa

Most Active Stocks on Oct. 26: RCT, NU and BBD Top Volume

$2.93 -$1.14

Vol: 204.08M (5.3x avg) Banking

SBS

▼ -26.09%

Companhia de saneamento Basico

$4.73 -$1.67

Vol: 54.76M (5.2x avg) Utilities

FAQ — GMAB

Why is GMAB moving today?

GMAB is up 2.04% in the current session. Scroll to the news section below to see the most recent headlines and catalysts driving the move.

Is Genmab A/S a good stock to buy today?

WeeklyTrader.io does not provide financial advice. Always verify catalysts, assess risk, and conduct your own research before making any investment decision.

What is GMAB's average volume?

Average volume for GMAB is approximately 4.14M shares per day based on the trailing 30 sessions.

Where can I see more stocks like GMAB?

Visit the sector filter on the gainers and losers pages to see related movers.